Literature DB >> 26541273

Histological pattern of Merkel cell carcinoma sentinel lymph node metastasis improves stratification of Stage III patients.

Jennifer S Ko1, Victor G Prieto2, Paul J Elson3, Ricardo E Vilain4, Melissa P Pulitzer5, Richard A Scolyer4, Jordan P Reynolds1, Melissa P Piliang1,6, Marc S Ernstoff7, Brian R Gastman8, Steven D Billings1.   

Abstract

Sentinel lymph node biopsy is used to stage Merkel cell carcinoma, but its prognostic value has been questioned. Furthermore, predictors of outcome in sentinel lymph node positive Merkel cell carcinoma patients are poorly defined. In breast carcinoma, isolated immunohistochemically positive tumor cells have no impact, but in melanoma they are considered significant. The significance of sentinel lymph node metastasis tumor burden (including isolated tumor cells) and pattern of involvement in Merkel cell carcinoma are unknown. In this study, 64 Merkel cell carcinomas involving sentinel lymph nodes and corresponding immunohistochemical stains were reviewed and clinicopathological predictors of outcome were sought. Five metastatic patterns were identified: (1) sheet-like (n=38, 59%); (2) non-solid parafollicular (n=4, 6%); (3) sinusoidal, (n=11, 17%); (4) perivascular hilar (n=1, 2%); and (5) rare scattered parenchymal cells (n=10, 16%). At the time of follow-up, 30/63 (48%) patients had died with 21 (33%) attributable to Merkel cell carcinoma. Patients with pattern 1 metastases had poorer overall survival compared with patients with patterns 2-5 metastases (P=0.03), with 22/30 (73%) deaths occurring in pattern 1 patients. Three (10%) deaths occurred in patients showing pattern 5, all of whom were immunosuppressed. Four (13%) deaths occurred in pattern 3 patients and 1 (3%) death occurred in a pattern 2 patient. In multivariable analysis, the number of positive sentinel lymph nodes (1 or 2 versus >2, P<0.0001), age (<70 versus ≥70, P=0.01), sentinel lymph node metastasis pattern (patterns 2-5 versus 1, P=0.02), and immune status (immunocompetent versus suppressed, P=0.03) were independent predictors of outcome, and could be used to stratify Stage III patients into three groups with markedly different outcomes. In Merkel cell carcinoma, the pattern of sentinel lymph node involvement provides important prognostic information and utilizing this data with other clinicopathological features facilitates risk stratification of Merkel cell carcinoma patients who may have management implications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26541273      PMCID: PMC5063050          DOI: 10.1038/modpathol.2015.109

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  33 in total

1.  Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.

Authors:  Bianca D Lemos; Barry E Storer; Jayasri G Iyer; Jerri Linn Phillips; Christopher K Bichakjian; L Christine Fang; Timothy M Johnson; Nanette J Liegeois-Kwon; Clark C Otley; Kelly G Paulson; Merrick I Ross; Siegrid S Yu; Nathalie C Zeitouni; David R Byrd; Vernon K Sondak; Jeffrey E Gershenwald; Arthur J Sober; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2010-06-19       Impact factor: 11.527

2.  Role of sentinel lymph node biopsy in patients with Merkel cell carcinoma: statistical analysis of 403 reported cases.

Authors:  Yoshitsugu Shibayama; Shinichi Imafuku; Akira Takahashi; Juichiro Nakayama
Journal:  Int J Clin Oncol       Date:  2014-04-01       Impact factor: 3.402

3.  Merkel cell carcinoma: what makes a difference?

Authors:  Jennifer Tseng; Birat Dhungel; Jane K Mills; Brian S Diggs; Roshanthi Weerasinghe; Jeanine Fortino; John T Vetto
Journal:  Am J Surg       Date:  2014-07-30       Impact factor: 2.565

4.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

5.  Merkel cell carcinoma. Prognosis and management.

Authors:  A Yiengpruksawan; D G Coit; H T Thaler; C Urmacher; W K Knapper
Journal:  Arch Surg       Date:  1991-12

6.  Clonal integration of a polyomavirus in human Merkel cell carcinoma.

Authors:  Huichen Feng; Masahiro Shuda; Yuan Chang; Patrick S Moore
Journal:  Science       Date:  2008-01-17       Impact factor: 47.728

7.  Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features.

Authors:  Michelle Heath; Natalia Jaimes; Bianca Lemos; Arash Mostaghimi; Linda C Wang; Pablo F Peñas; Paul Nghiem
Journal:  J Am Acad Dermatol       Date:  2008-03       Impact factor: 11.527

Review 8.  Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND)--ACOSOG Z0011 results and beyond.

Authors:  Wolfgang Gatzemeier; G Bruce Mann
Journal:  Breast       Date:  2013-03-09       Impact factor: 4.380

Review 9.  Milestones in the staging, classification, and biology of Merkel cell carcinoma.

Authors:  Ata S Moshiri; Paul Nghiem
Journal:  J Natl Compr Canc Netw       Date:  2014-09       Impact factor: 11.908

Review 10.  Prognostic significance of sentinel lymph node mapping in Merkel cell carcinoma: systematic review and meta-analysis of prognostic studies.

Authors:  Ramin Sadeghi; Zohreh Adinehpoor; Masoud Maleki; Babak Fallahi; Luca Giovanella; Giorgio Treglia
Journal:  Biomed Res Int       Date:  2014-05-26       Impact factor: 3.411

View more
  5 in total

Review 1.  Merkel Cell Carcinoma.

Authors:  Melissa Pulitzer
Journal:  Surg Pathol Clin       Date:  2017-03-14

2.  Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma.

Authors:  Richard J Straker; Michael J Carr; Andrew J Sinnamon; Adrienne B Shannon; James Sun; Karenia Landa; Kirsten M Baecher; Christian Wood; Kevin Lynch; Harrison G Bartels; Robyn Panchaud; Michael C Lowe; Craig L Slingluff; Mark J Jameson; Kenneth Tsai; Mark B Faries; Georgia M Beasley; Vernon Sondak; Giorgos C Karakousis; Jonathan S Zager; John T Miura
Journal:  Ann Surg Oncol       Date:  2021-04-22       Impact factor: 5.344

Review 3.  Merkel Cell Carcinoma Therapeutic Update.

Authors:  Nicole M Cassler; Dean Merrill; Christopher K Bichakjian; Isaac Brownell
Journal:  Curr Treat Options Oncol       Date:  2016-07

4.  Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Christopher K Bichakjian; Thomas Olencki; Sumaira Z Aasi; Murad Alam; James S Andersen; Rachel Blitzblau; Glen M Bowen; Carlo M Contreras; Gregory A Daniels; Roy Decker; Jeffrey M Farma; Kris Fisher; Brian Gastman; Karthik Ghosh; Roy C Grekin; Kenneth Grossman; Alan L Ho; Karl D Lewis; Manisha Loss; Daniel D Lydiatt; Jane Messina; Kishwer S Nehal; Paul Nghiem; Igor Puzanov; Chrysalyne D Schmults; Ashok R Shaha; Valencia Thomas; Yaohui G Xu; John A Zic; Karin G Hoffmann; Anita M Engh
Journal:  J Natl Compr Canc Netw       Date:  2018-06       Impact factor: 12.693

5.  Clinical Features and Prognosis of Merkel Cell Carcinoma in Elderly Patients.

Authors:  YiJun Xia; DongSheng Cao; Jun Zhao; BangZhong Zhu; Juan Xie
Journal:  Med Sci Monit       Date:  2020-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.